CL2004001852A1 - Parche transdermico, formulacion oral y formulacion parenteral que comprenden estrogeno; uso para tratar uno o mas de: osteoporosis, dolores de cabeza, nausea, depresion, calores repentinos, decrecimiento en densidad de minerales en hueso y riesgo o - Google Patents
Parche transdermico, formulacion oral y formulacion parenteral que comprenden estrogeno; uso para tratar uno o mas de: osteoporosis, dolores de cabeza, nausea, depresion, calores repentinos, decrecimiento en densidad de minerales en hueso y riesgo oInfo
- Publication number
- CL2004001852A1 CL2004001852A1 CL200401852A CL2004001852A CL2004001852A1 CL 2004001852 A1 CL2004001852 A1 CL 2004001852A1 CL 200401852 A CL200401852 A CL 200401852A CL 2004001852 A CL2004001852 A CL 2004001852A CL 2004001852 A1 CL2004001852 A1 CL 2004001852A1
- Authority
- CL
- Chile
- Prior art keywords
- strogen
- risk
- treat
- formulation
- bone
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title 2
- 239000000203 mixture Substances 0.000 title 2
- 206010019233 Headaches Diseases 0.000 title 1
- 206010028813 Nausea Diseases 0.000 title 1
- 208000001132 Osteoporosis Diseases 0.000 title 1
- 210000000988 bone and bone Anatomy 0.000 title 1
- 229910052500 inorganic mineral Inorganic materials 0.000 title 1
- 239000011707 mineral Substances 0.000 title 1
- 230000008693 nausea Effects 0.000 title 1
- 208000010392 Bone Fractures Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Otolaryngology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
LA PRESENTE INVENCION PROPORCIONA METODOS PARA TRATAR CONDICIONES FISICAS QUE RESULTAN DE DECLIVE EN ESTROGENO POST-MENOPAUSICO EN UN SUJETO PORST-MENOPAUSICO, Y EN PARTICULAR METODOS PARA REDUCIR EL RIESGO DE FRACTURAS DE HUESO OSTEOPOROSICO EN UN SUJETO POST-MENOPAUSICO. LA PRESENTE INVENCION TAMBIEN PROPORCIONA UN EQUIPO UTIL PARA LLEVAR A CABO LOS METODOS DE LA PRESENTE INVENCION.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/975,599 US5891868A (en) | 1997-11-21 | 1997-11-21 | Methods for treating postmenopausal women using ultra-low doses of estrogen |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2004001852A1 true CL2004001852A1 (es) | 2005-06-03 |
Family
ID=25523181
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL200401852A CL2004001852A1 (es) | 1997-11-21 | 2004-07-23 | Parche transdermico, formulacion oral y formulacion parenteral que comprenden estrogeno; uso para tratar uno o mas de: osteoporosis, dolores de cabeza, nausea, depresion, calores repentinos, decrecimiento en densidad de minerales en hueso y riesgo o |
Country Status (26)
Country | Link |
---|---|
US (1) | US5891868A (es) |
EP (2) | EP1570848B1 (es) |
JP (2) | JP2001523722A (es) |
KR (1) | KR100576568B1 (es) |
CN (1) | CN100398110C (es) |
AT (2) | ATE383862T1 (es) |
AU (1) | AU760108B2 (es) |
BR (1) | BR9814984A (es) |
CA (1) | CA2306881C (es) |
CL (1) | CL2004001852A1 (es) |
CZ (1) | CZ299226B6 (es) |
DE (2) | DE69829501T2 (es) |
EA (1) | EA004573B1 (es) |
EE (1) | EE04221B1 (es) |
ES (2) | ES2299912T3 (es) |
HK (1) | HK1082919A1 (es) |
HU (1) | HUP0004339A3 (es) |
IL (1) | IL136175A (es) |
IS (1) | IS2132B (es) |
NO (1) | NO326929B1 (es) |
NZ (1) | NZ504668A (es) |
PL (1) | PL193897B1 (es) |
PT (1) | PT1032398E (es) |
SK (1) | SK284971B6 (es) |
TR (1) | TR200001460T2 (es) |
WO (1) | WO1999026631A1 (es) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6407082B1 (en) * | 1996-09-13 | 2002-06-18 | New Life Pharmaceuticals Inc. | Prevention of ovarian cancer by administration of a vitamin D compound |
US6511970B1 (en) | 1996-09-13 | 2003-01-28 | New Life Pharmaceuticals Inc. | Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium |
US6765002B2 (en) | 2000-03-21 | 2004-07-20 | Gustavo Rodriguez | Prevention of ovarian cancer by administration of products that induce transforming growth factor-β and/or apoptosis in the ovarian epithelium |
US6034074A (en) | 1996-09-13 | 2000-03-07 | New Life Pharmaceuticals Inc. | Prevention of ovarian cancer by administration of a Vitamin D compound |
US6028064A (en) | 1996-09-13 | 2000-02-22 | New Life Pharmaceuticals Inc. | Prevention of ovarian cancer by administration of progestin products |
US6692763B1 (en) * | 1998-11-19 | 2004-02-17 | The Regents Of The University Of California | Methods for treating postmenopausal women using ultra-low doses of estrogen |
US5891868A (en) * | 1997-11-21 | 1999-04-06 | Kaiser Foundation Health Plan, Inc. | Methods for treating postmenopausal women using ultra-low doses of estrogen |
US6787531B1 (en) * | 1999-08-31 | 2004-09-07 | Schering Ag | Pharmaceutical composition for use as a contraceptive |
CA2396098A1 (en) * | 2000-01-14 | 2001-07-19 | Sterix Limited | Pharmaceutical compositions containing steroidal structures and uses thereof |
US20020132801A1 (en) * | 2001-01-11 | 2002-09-19 | Schering Aktiengesellschaft | Drospirenone for hormone replacement therapy |
US20050113351A1 (en) * | 2000-03-21 | 2005-05-26 | Rodriguez Gustavo C. | Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium |
US20010044431A1 (en) * | 2000-03-21 | 2001-11-22 | Rodriguez Gustavo C. | Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium |
US20040176336A1 (en) * | 2000-03-21 | 2004-09-09 | Rodriguez Gustavo C. | Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium |
EP1334367B1 (en) * | 2000-10-13 | 2006-06-07 | Abbott Laboratories | A method of determining the initial dose of vitamin d compounds |
WO2003011282A1 (en) | 2001-07-31 | 2003-02-13 | Pfizer Products Inc. | Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists/antagonists, estrogens and progestins |
WO2005011618A2 (en) * | 2003-07-31 | 2005-02-10 | Ivax Corporation | Methods for the treatment of male and female sexual dysfunction |
US7685012B2 (en) * | 2003-12-30 | 2010-03-23 | Wilson Thomas W | Method and system for analyzing resource allocation based on cohort times |
US20060040904A1 (en) * | 2004-08-17 | 2006-02-23 | Ahmed Salah U | Vaginal cream compositions, kits thereof and methods of using thereof |
US8022053B2 (en) * | 2004-11-02 | 2011-09-20 | Bayer Schering Pharma Aktiengesellschaft | Oral solid dosage forms containing a low dose of estradiol |
CA2601773A1 (en) * | 2005-02-03 | 2006-08-10 | Duramed Pharmaceuticals, Inc. | Compositions of unconjugated estrogens and methods for their use |
US8834862B2 (en) * | 2005-04-19 | 2014-09-16 | Nanocyte Inc. | Methods, compositions and devices utilizing stinging cells/capsules for conditioning a tissue prior to delivery of an active agent |
US8217024B2 (en) * | 2005-12-27 | 2012-07-10 | Teva Women's Health, Inc. | Conjugated estrogen compositions, applicators, kits, and methods of making and use thereof |
US20070254036A1 (en) * | 2006-04-13 | 2007-11-01 | Besins Healthcare Sa | Treatment of menopause associated symptoms |
CN104398496B (zh) * | 2007-10-15 | 2018-03-20 | 阿尔扎公司 | 芬太尼的一天更换一次透皮施用 |
US20090110656A1 (en) * | 2007-10-31 | 2009-04-30 | Lemke Sarah A | Skin cooling composition |
US20090157153A1 (en) * | 2007-12-13 | 2009-06-18 | Sarah Anne Lemke | Skin cooling system |
DE102009007771B4 (de) | 2009-02-05 | 2012-02-16 | Bayer Schering Pharma Aktiengesellschaft | Bukkales Applikationssystem, 17α-Estradiol enthaltend |
CN106038574A (zh) * | 2010-04-15 | 2016-10-26 | 拜耳知识产权有限责任公司 | 用于hrt的低剂量的固体口服剂型 |
HUP1000335A2 (en) * | 2010-06-22 | 2012-02-28 | Avidin Kft | Use of an estrogen derivative for the treatment and/or prevention of psychiatric conditions |
RU2456955C1 (ru) * | 2011-03-01 | 2012-07-27 | Государственное образовательное учреждение высшего профессионального образования "Алтайский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию" | Способ ортопедического лечения женщин постменопаузального периода съемными пластиночными протезами |
CN102397550B (zh) * | 2011-08-30 | 2013-05-08 | 广东医学院 | 一组由阿司匹林与雌激素组成的防治骨质疏松症的药物组合物 |
JP2013097693A (ja) * | 2011-11-04 | 2013-05-20 | Hitachi Solutions Ltd | 骨粗鬆症リスク判定システム及びプログラム |
HRP20211377T1 (hr) | 2011-11-23 | 2022-01-07 | Therapeuticsmd, Inc. | Prirodne kombinirane hormonske supstitucijske formulacije i terapije |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US20150098983A1 (en) * | 2013-10-07 | 2015-04-09 | Teikoku Pharma Usa, Inc. | Methods and Compositions for Treating Withdrawal Syndromes Using Non-Sedative Dexmedetomidine Transdermal Compositions |
CA2947767A1 (en) | 2014-05-22 | 2015-11-26 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
JP2019513709A (ja) | 2016-04-01 | 2019-05-30 | セラピューティックスエムディー インコーポレーテッドTherapeuticsmd, Inc. | ステロイドホルモン薬学的組成物 |
US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3598123A (en) * | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3797494A (en) * | 1969-04-01 | 1974-03-19 | Alza Corp | Bandage for the administration of drug by controlled metering through microporous materials |
US4031894A (en) * | 1975-12-08 | 1977-06-28 | Alza Corporation | Bandage for transdermally administering scopolamine to prevent nausea |
US4722941A (en) * | 1978-06-07 | 1988-02-02 | Kali-Chemie Pharma Gmbh | Readily absorbable pharmaceutical compositions of per se poorly absorbable pharmacologically active agents and preparation thereof |
US4460372A (en) * | 1981-02-17 | 1984-07-17 | Alza Corporation | Percutaneous absorption enhancer dispenser for use in coadministering drug and percutaneous absorption enhancer |
US4573996A (en) * | 1984-01-03 | 1986-03-04 | Jonergin, Inc. | Device for the administration of an active agent to the skin or mucosa |
US4624665A (en) * | 1984-10-01 | 1986-11-25 | Biotek, Inc. | Method of transdermal drug delivery |
SE8602666D0 (sv) * | 1986-06-16 | 1986-06-16 | Leo Ab | Intravaginal devices |
US5188835A (en) * | 1986-06-16 | 1993-02-23 | Kabi Pharmacia Ab | Intravaginal devices |
US5223261A (en) * | 1988-02-26 | 1993-06-29 | Riker Laboratories, Inc. | Transdermal estradiol delivery system |
US5340586A (en) * | 1991-04-12 | 1994-08-23 | University Of Southern California | Methods and formulations for use in treating oophorectomized women |
JP2960832B2 (ja) * | 1992-05-08 | 1999-10-12 | ペルマテック テクノロジー アクチェンゲゼルシャフト | エストラジオールの投与システム |
US5460820B1 (en) * | 1993-08-03 | 1999-08-03 | Theratech Inc | Method for providing testosterone and optionally estrogen replacement therapy to women |
US5891868A (en) * | 1997-11-21 | 1999-04-06 | Kaiser Foundation Health Plan, Inc. | Methods for treating postmenopausal women using ultra-low doses of estrogen |
-
1997
- 1997-11-21 US US08/975,599 patent/US5891868A/en not_active Expired - Lifetime
-
1998
- 1998-11-19 IL IL13617598A patent/IL136175A/xx not_active IP Right Cessation
- 1998-11-19 PL PL98341112A patent/PL193897B1/pl unknown
- 1998-11-19 ES ES05006108T patent/ES2299912T3/es not_active Expired - Lifetime
- 1998-11-19 DE DE69829501T patent/DE69829501T2/de not_active Expired - Lifetime
- 1998-11-19 PT PT98960277T patent/PT1032398E/pt unknown
- 1998-11-19 TR TR2000/01460T patent/TR200001460T2/xx unknown
- 1998-11-19 CA CA002306881A patent/CA2306881C/en not_active Expired - Fee Related
- 1998-11-19 CZ CZ20001602A patent/CZ299226B6/cs not_active IP Right Cessation
- 1998-11-19 JP JP2000521833A patent/JP2001523722A/ja not_active Withdrawn
- 1998-11-19 WO PCT/US1998/024677 patent/WO1999026631A1/en active IP Right Grant
- 1998-11-19 SK SK733-2000A patent/SK284971B6/sk not_active IP Right Cessation
- 1998-11-19 CN CNB988113597A patent/CN100398110C/zh not_active Expired - Fee Related
- 1998-11-19 BR BR9814984-9A patent/BR9814984A/pt not_active Application Discontinuation
- 1998-11-19 IS IS5468A patent/IS2132B/xx unknown
- 1998-11-19 HU HU0004339A patent/HUP0004339A3/hu unknown
- 1998-11-19 EE EEP200000307A patent/EE04221B1/xx not_active IP Right Cessation
- 1998-11-19 ES ES98960277T patent/ES2241188T3/es not_active Expired - Lifetime
- 1998-11-19 NZ NZ504668A patent/NZ504668A/xx not_active IP Right Cessation
- 1998-11-19 EP EP05006108A patent/EP1570848B1/en not_active Expired - Lifetime
- 1998-11-19 KR KR1020007005461A patent/KR100576568B1/ko not_active IP Right Cessation
- 1998-11-19 AU AU15914/99A patent/AU760108B2/en not_active Ceased
- 1998-11-19 AT AT05006108T patent/ATE383862T1/de not_active IP Right Cessation
- 1998-11-19 DE DE69839026T patent/DE69839026T2/de not_active Expired - Lifetime
- 1998-11-19 AT AT98960277T patent/ATE291430T1/de active
- 1998-11-19 EP EP98960277A patent/EP1032398B1/en not_active Expired - Lifetime
- 1998-11-19 EA EA200000563A patent/EA004573B1/ru not_active IP Right Cessation
-
2000
- 2000-05-19 NO NO20002587A patent/NO326929B1/no not_active IP Right Cessation
-
2003
- 2003-12-09 JP JP2003411088A patent/JP2004083599A/ja active Pending
-
2004
- 2004-07-23 CL CL200401852A patent/CL2004001852A1/es unknown
-
2006
- 2006-03-06 HK HK06102902A patent/HK1082919A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2004001852A1 (es) | Parche transdermico, formulacion oral y formulacion parenteral que comprenden estrogeno; uso para tratar uno o mas de: osteoporosis, dolores de cabeza, nausea, depresion, calores repentinos, decrecimiento en densidad de minerales en hueso y riesgo o | |
MY131835A (en) | Permanent, removable tissue markings | |
DE50007524D1 (de) | Vorrichtung zur fixation von knochen, insbesondere von wirbelkörpern relativ zueinander | |
FR16C0028I2 (fr) | Vecteurs viraux et utilisation de ces derniers dans des methodes therapeutiques | |
HN1998000157A (es) | Agonistas de prostaglandinas | |
WO2001076514A3 (en) | Methods and devices for treating fractured and/or diseased bone | |
TR199801679T2 (xx) | Osteoporoz i�in birle�tirme terapisi. | |
BR0207279A (pt) | Dispositivo de injeção de vertebroplastia e cimento para osso para o mesmo | |
ES2191152T3 (es) | Terapia combinada para el tratamiento de psicosis. | |
ES2171263T3 (es) | Metodo para dispensar articulos absorbentes. | |
GB2423935B (en) | Bone plates | |
WO2004045389A3 (en) | Adjustable bone plates | |
IL143901A0 (en) | Use of cyclooxygenase-2- inhibitor, a matrix metallaproteinase inhibitor, an antineoplastic agent and optionally radiation as a combination treatment of neoplasia | |
MX345196B (es) | Métodos y aparatos para la conservación ósea. | |
BR0105457A (pt) | Combinações terapêuticas para estimulação do crescimento ósseo | |
BR9807564A (pt) | Sistema de barbear a úmido. | |
BRPI0508678A (pt) | emplastro para provisão de terapia a um indivìduo, método para provisão de terapia a um indivìduo e método de fabricação de um emplatro que provê terapia a um indivìduo | |
YU76100A (sh) | Pirolo(2,3-d) pirimidin preparati i njihova primena | |
CY1107531T1 (el) | Χρηση αναστολεων πρωτεασομης για την αγωγη των διαταραχων ξηρου οφθαλμου | |
CR7608A (es) | Derivados de ciclotiocarbamativa como moduladores de rp y uso de los mismos para tratamiento de trastornos de la piel | |
AR016981A2 (es) | Polipeptidos sinteticos | |
ATE483467T1 (de) | Verfahren zum schutz vor strahlung mit flagellin | |
WO2004024893A3 (en) | Nell-1 enhanced bone mineralization | |
BR0314362A (pt) | Método para previnir ou reduzir fraturas secundárias após fratura de quadril | |
DE60326326D1 (de) | Marknagel zur fixierung von knochenfragmenten bei knochenfrakturen |